The Technical Document on Human Growth Hormone (hGH) Isoform Differential Immunoassays for Doping Control Analyses, TD2021GH, has been aligned with the 2021 World Anti-Doping Code (Code) and the recently approved 2021 International Standard for Laboratories (ISL); and, the other International Standards which are set to come into force on 1 January 2021.

The main changes in the TD2021GH include:

**Article 2.0 Assay Requirements**
- The section on assay technical requirements has been split into two articles: 2.1 Test Method Validation Requirements and 2.2 Test Method Accreditation Requirements.

**Article 2.3 Assay Pre-Analytical Procedure**
- It has been clarified that “A” Sample serum fractions obtained from Samples received as whole blood (in SST™-II tubes or SST™-II Plus Advance tubes or SST™ tubes) and not used for the Initial Testing Procedure may be stored frozen in the Sample collection tube according to the tube manufacturer’s instructions until analysis.

**Article 3.2 Reporting of Test Results**
- The requirement to report the expanded Measurement Uncertainty ($U_{95\%}$) for the analytical value of the recGH/pitGH ratio has been eliminated, in line with the changes established for the reporting of other Threshold Substances in the TD DL. The reporting of the recGH / pitGH ratio at levels higher than the Decision Limit (DL), and of a compliant relative combined standard Measurement Uncertainty ($u_c$, %) at values close to the DL, as determined by the Laboratory during Test Method validation, are sufficient for reporting an Adverse Analytical Finding (AAF).

**Article 4.0 Measurement Uncertainty**
- It has been clarified that, in equations 1 and 2, the $u_c$ shall be the relative $u_c$, expressed in %.

In addition:
- Formatting as well as updating of terms and definitions, where relevant;
- Footnotes have been inserted as Comments where relevant in the main text.

The TD2021GH replaces the former TD2019GH and becomes effective on 1 April 2021.